CELC
HealthcareCelcuity Inc. · Biotechnology · $7B
What is Celcuity Inc.?
Celcuity Inc. is a clinical-stage biotechnology company focused on developing molecularly targeted cancer therapies. Based in Minneapolis, Minnesota, the company pairs a proprietary diagnostic platform with a lead drug candidate licensed from Pfizer.
Celcuity's core approach centers on its CELsignia diagnostic platform, which uses living tumor cells to identify the specific cellular process driving a patient's cancer. That insight is then matched to a targeted therapy. The company's lead drug candidate, Gedatolisib, targets PI3K and mTOR pathways and is being studied in patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. Celcuity holds commercialization rights to Gedatolisib through a license agreement with Pfizer.
Celcuity was founded in 2011 and is headquartered in Minneapolis, Minnesota.
- CELsignia diagnostic platform for living tumor cell analysis
- Gedatolisib — PI3K and mTOR inhibitor in clinical development
- CELsignia MP test for HER2, c-Met, and PI3K signaling in breast and ovarian tumors
- Precision oncology pipeline targeting advanced breast cancer
Is CELC a Good Stock to Buy?
UQS Score rates CELC as Poor overall, reflecting the early-stage nature of the business across multiple evaluation pillars.
Among the five pillars, Risk registers as Neutral — suggesting the company's financial risk profile is not at the extreme end for a clinical-stage biotech. That relative stability in risk may reflect its Pfizer partnership and focused pipeline.
Quality, Moat, Growth, and Valuation all score at the weaker end of the scale. With no approved products generating revenue, the company carries structural weaknesses typical of pre-commercial biotechs, and the current Valuation pillar reads as Elevated.
See the full pillar breakdown and underlying financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does CELC pay dividends?
No — Celcuity Inc. does not currently pay a dividend.
Celcuity does not pay a dividend, which is standard for clinical-stage biotechnology companies. Capital is directed toward research, clinical trials, and pipeline advancement rather than shareholder distributions. Investors in CELC are typically seeking potential long-term appreciation tied to drug development outcomes rather than income.
When does CELC report earnings?
Celcuity reports financial results on a quarterly cadence, consistent with US-listed public companies.
As a pre-revenue clinical-stage company, quarterly results center on cash runway, operating expenses, and clinical trial progress rather than traditional revenue or profit metrics. Pipeline milestones and trial readouts tend to drive more market attention than earnings beats.
For the most recent quarter's results and management commentary, visit Celcuity's investor relations page directly.
CELC Price History
+365.4% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Celcuity Inc.?
Based on Celcuity Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
CELC Long-term Outlook
Celcuity's Growth pillar is rated Weak, reflecting the absence of commercial revenue and the long timelines inherent in oncology drug development. The path to value creation runs through clinical trial outcomes for Gedatolisib and potential regulatory milestones. The Elevated Valuation pillar suggests the market has already priced in meaningful optimism, which creates asymmetric risk if trial results disappoint. The Neutral Risk pillar provides some grounding, but the overall outlook is highly binary — typical for single-asset clinical-stage biotechs.
Growth drivers
- Positive clinical trial data for Gedatolisib in advanced breast cancer
- Expansion of CELsignia diagnostic platform to additional tumor types
- Pfizer partnership providing development and commercialization infrastructure
Key risks
- Clinical trial failure or regulatory setbacks for Gedatolisib
- Elevated valuation leaving limited margin of safety if milestones slip
- Dependence on external funding given pre-revenue status
CELC vs Peers
Celcuity operates in a competitive clinical-stage oncology space alongside several peers pursuing targeted cancer therapies.
Centessa operates a multi-asset portfolio model across several disease areas, offering broader pipeline diversification than Celcuity's focused breast cancer approach.
Erasca concentrates on RAS/MAPK pathway cancers, giving it a distinct mechanistic focus compared to Celcuity's PI3K and mTOR targeting strategy.
Immunovant pursues autoimmune indications rather than oncology, representing a different therapeutic category despite sharing the clinical-stage development profile.
Frequently Asked Questions
What does Celcuity do?
Celcuity is a clinical-stage biotech developing targeted cancer therapies. Its CELsignia platform analyzes living tumor cells to identify which cellular process is driving a patient's cancer, then matches that to a targeted treatment. Its lead drug, Gedatolisib, is being studied in advanced breast cancer under a license from Pfizer.
Does CELC pay dividends?
No, Celcuity does not pay a dividend. As a pre-revenue clinical-stage company, available capital is allocated to clinical trials and research rather than shareholder distributions. Dividend payments are not typical for companies at this stage of development.
When does CELC report earnings?
Celcuity follows a standard quarterly reporting cadence for US-listed companies. Because it is pre-revenue, results focus on operating expenses and cash position rather than sales figures. Check Celcuity's investor relations page for the most current schedule.
Is CELC a good stock to buy?
UQS Score rates CELC as Poor overall, with Weak readings across Quality, Moat, and Growth pillars, and an Elevated Valuation. That profile reflects the high uncertainty of clinical-stage biotech investing. Whether it fits a portfolio depends on individual risk tolerance and investment thesis. View the full analysis on UQS Pro.
Is CELC overvalued?
The UQS Valuation pillar for CELC is rated Elevated, suggesting the current market price embeds significant optimism about future clinical outcomes. For a company with no approved products, that leaves limited margin of safety if development timelines extend or trial results disappoint.
How does CELC compare to its competitors?
Celcuity is narrowly focused on PI3K and mTOR-driven breast cancer, which differentiates it from peers like Erasca, which targets RAS/MAPK pathways, and Immunovant, which works in autoimmune disease. Centessa offers broader pipeline diversification. Each company carries its own clinical and financial risk profile.
What is CELC's market cap bracket?
Celcuity is classified as a mid-cap company. Within the clinical-stage biotech universe, mid-cap status can reflect market anticipation of pipeline potential rather than current revenues, since the company has not yet commercialized any products.
Who founded Celcuity?
Celcuity was founded in 2011 and is headquartered in Minneapolis, Minnesota. Detailed founding history and leadership background are publicly available through the company's official website and SEC filings.
Is CELC a long-term quality investment?
As a long-term quality indicator, UQS rates CELC as Poor. The Weak readings on Quality, Moat, and Growth pillars reflect the absence of durable competitive advantages and commercial revenue at this stage. Long-term outcomes depend heavily on clinical trial success, which remains uncertain.
What is the main competitive advantage of Celcuity?
Celcuity's potential differentiator is its CELsignia diagnostic platform, which uses living tumor cells rather than static genetic markers to identify treatment targets. If validated clinically, this approach could enable more precise patient selection. However, the Moat pillar is currently rated Weak, reflecting that this advantage is not yet commercially established.
Is CELC a growth stock or value stock?
Based on UQS pillar labels, CELC carries a Weak Growth rating and an Elevated Valuation — an unusual combination that reflects speculative pricing of future clinical potential rather than current business performance. It does not fit neatly into either traditional growth or value categories.
Unlock Full CELC Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View exact UQS pillar scores across all five dimensions
- ✓Access detailed financial metrics and trend data
- ✓Compare CELC against sector peers side by side
- ✓Track Quality, Risk, and Valuation changes over time
- ✓Get the complete analyst-grade breakdown in one view
Pro Analysis
CELC — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 16, 2026 | 12.2 | 0.0 | 13.0 | 0.0 | 59.7 | 0.0 | -3.8 |
| May 10, 2026 | 16.0 | 0.0 | 13.0 | 18.8 | 59.7 | 0.3 | +3.7 |
| May 9, 2026 | 12.3 | 0.0 | 13.0 | 0.0 | 59.7 | 0.5 | -3.7 |
| May 6, 2026 | 16.0 | 0.0 | 13.0 | 18.8 | 59.7 | 0.3 | +3.8 |
| Apr 2, 2026 | 12.2 | 0.0 | 13.0 | 0.0 | 59.7 | 0.0 | — |
CELC — Pillar Breakdown
Quality
— 0.0/100 (25%)Celcuity Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 0.0/100 (20%)Celcuity Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 59.7/100 (15%)Celcuity Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Celcuity Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 13/100 (25%)Celcuity Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for CELC.
Score Composition
Financial Data
More Stock Analysis
How is the CELC UQS Score Calculated?
The UQS (Unified Quality Score) for Celcuity Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Celcuity Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Celcuity Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.